Agilent Technologies, Inc. (NYSE:A) Position Boosted by Headlands Technologies LLC

Headlands Technologies LLC boosted its position in Agilent Technologies, Inc. (NYSE:A) by 647.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,744 shares of the medical research company’s stock after buying an additional 10,172 shares during the quarter. Headlands Technologies LLC’s holdings in Agilent Technologies were worth $1,522,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Livelsberger Financial Advisory acquired a new position in shares of Agilent Technologies in the 4th quarter valued at about $26,000. Crewe Advisors LLC lifted its holdings in Agilent Technologies by 114.8% in the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after acquiring an additional 101 shares during the last quarter. Ridgewood Investments LLC acquired a new position in Agilent Technologies in the second quarter valued at approximately $29,000. Rise Advisors LLC grew its holdings in shares of Agilent Technologies by 527.8% during the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 190 shares during the last quarter. Finally, YHB Investment Advisors Inc. acquired a new stake in shares of Agilent Technologies during the 1st quarter worth approximately $34,000. Institutional investors and hedge funds own 87.42% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on A. Jefferies Financial Group restated a “hold” rating and set a $135.00 price objective (down previously from $152.00) on shares of Agilent Technologies in a research report on Monday, June 3rd. Wells Fargo & Company assumed coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price target for the company. Citigroup lifted their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Wolfe Research lowered shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a research note on Thursday, May 30th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.60.

Agilent Technologies Stock Down 0.0 %

A opened at $138.04 on Wednesday. The stock’s fifty day moving average is $136.08 and its 200-day moving average is $139.17. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $155.35. The company has a market capitalization of $40.27 billion, a PE ratio of 32.63, a P/E/G ratio of 6.36 and a beta of 1.05. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. Agilent Technologies’s revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.43 EPS. On average, equities analysts predict that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.33% of the stock is currently owned by company insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.